Clinical trials: Squamous-Cell Lung Cancer
Solid Tumor, Advanced Cancer
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary…
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05076760
- Testing
- MEM-288 Intratumoral Injection, Nivolumab, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memgen, Inc.
Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
This study will explore the correlation of biomarkers with response rate, and the overall efficacy and safety, of Avastin in combination with carboplatin-based chemotherapy in patients with advanced or recurrent non-squamous…
- Trial name
- NCT00700180
- Testing
- bevacizumab [Avastin], Carboplatin-based chemotherapy
- Where
- 59 sites in Australia, Belgium and 14 more
- Volunteers
- 303 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
The objective of this study is to test a clinical benefit of the addition of CP 751,871 to erlotinib therapy in patients with advanced NSCLC of non adenocarcinoma histology. The primary endpoint is Overall Survival (OS).
- Conditions
- Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Adenosquamous Cell
- Trial name
- NSCLC (NCT00673049)
- Testing
- CP 751,871 (Figitumumab), Erlotinib
- Where
- 175 sites in United States, Belgium and 25 more
- Volunteers
- 583 people
- Sponsor
- Pfizer
Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma
A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer
Patients in the Phase 1b part of the study will be treated with ilixadencel at an increasing dose and frequency, in combination with standard doses and schedules of checkpoint inhibitor (CPI) pembrolizumab.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Non-small Cell Lung Cancer
- Trial name
- ILIAD (NCT03735290)
- Testing
- ilixadencel, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Mendus
Non-Squamous Non-Small Cell Lung Cancer
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
This open-label, randomized, multicenter study will evaluate the efficacy and safety of bevacizumab (Avastin) in combination with standard of care (SOC) treatment in participants with advanced non-squamous NSCLC.
- Trial name
- NCT01351415
- Testing
- Bevacizumab, Docetaxel, Erlotinib
- Where
- 179 sites in United States, Argentina and 16 more
- Volunteers
- 485 people
- Sponsor
- Hoffmann-La Roche
KRAS Positive Patients With Non-small Cell Lung Cancer, Squamous Cell Non-small Cell Lung Cancer
A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer
BIND-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation positive or squamous cell non-small cell lung cancer (NSCLC) who…
- Trial name
- NCT02283320
- Testing
- BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)
- Where
- 32 sites in United States, Russia
- Volunteers
- 69 people
- Sponsor
- BIND Therapeutics
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
This study is being done to find out the side effects (unwanted effects) that are caused in patients with cancers who are given SGN-2FF.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Breast Neoplasms, Urinary Bladder Neoplasm
- Trial name
- NCT02952989
- Testing
- SGN-2FF, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- Seagen Inc.
Non Squamous, Non-small-cell Lung Cancer
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
This study is to determine if the combination regimen of tivantinib with erlotinib will improve overall survival relative to erlotinib alone in subjects with locally advanced or metastatic non-squamous, non-small cell lung cancer…
- Trial name
- NCT01244191
- Testing
- Tivantinib, Erlotinib
- Where
- 304 sites in United States, Argentina and 21 more
- Volunteers
- 1,048 people
- Sponsor
- Daiichi Sankyo
Non-Squamous Non-Small Cell Lung Cancer
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
This study will assess the prevalence of epidermal growth factor receptor (EGFR) mutations in newly diagnosed patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT01250119
- Testing
- erlotinib [Tarceva]
- Where
- 22 sites in United Kingdom
- Volunteers
- 688 people
- Sponsor
- Hoffmann-La Roche
Bladder Cancer, Squamous Cell Carcinoma of the Lung
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have…
- Conditions
- Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma
- Trial name
- NCT07217171
- Testing
- EVOLVE104
- Where
- 16 sites in United States
- Volunteers
- 160 people
- Sponsor
- EvolveImmune United, Inc
NSCLC
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
This is a phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 and AK112 With or Without Chemotherapy for NSCLC patients.
- Trial name
- NCT05636267
- Testing
- AK119, AK112, Pemetrexed
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Akeso
Neoplasms
Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
This trial will evaluate safety and tolerability of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with non-small cell lung cancer.
- Trial name
- NCT03709706
- Testing
- Lete-cel, Pembrolizumab
- Where
- 31 sites in United States, Canada and 3 more
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety…
- Trial name
- NCT02900664
- Testing
- PDR001, ACZ885, CJM112
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 283 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC
This is a multinational, double-blind, randomized, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of bevacizumab-Pfizer plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and…
- Trial name
- NCT02364999
- Testing
- Bevacizumab-Pfizer, Bevacizumab-EU, Paclitaxel
- Where
- 263 sites in United States, Australia and 25 more
- Volunteers
- 719 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS…
- Trial name
- Krascendo 2 (NCT06793215)
- Testing
- Divarasib, Pembrolizumab, Pemetrexed
- Where
- 288 sites in United States, Argentina and 26 more
- Volunteers
- 600 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease.
- Trial name
- LIVIGNO-4 (NCT06236438)
- Testing
- Livmoniplimab, Budigalimab, Pembrolizumab
- Where
- 61 sites in United States, Australia and 10 more
- Volunteers
- 167 people
- Sponsor
- AbbVie
Non-Small Cell Lung Cancer
Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)
The purpose of study is to compare the efficacy and safety of ONO-4538 in combination with carboplatin, paclitaxel, and bevacizumab (ONO-4538 group) to placebo in combination with carboplatin, paclitaxel, and bevacizumab (placebo…
- Trial name
- NCT03117049
- Testing
- ONO-4538, Carboplatin, Paclitaxel
- Where
- 135 sites in Japan, South Korea and 1 more
- Volunteers
- 550 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Squamous Non-Small Cell Lung Cancer
Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC
The main purpose of the study was to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in participants with treatment-naïve advanced squamous non-small-cell lung…
- Trial name
- NCT03717155
- Testing
- Avelumab, Cetuximab, Gemcitabine
- Where
- 20 sites in Hungary, Serbia and 1 more
- Volunteers
- 43 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Tumors
A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
The purpose of this study is to determine the safety, tolerability and efficacy of combretastatin A4 phosphate (CA4P), also known as fosbretabulin, in combination with bevacizumab (Avastin), carboplatin and paclitaxel in patients…
- Trial name
- FALCON (NCT00653939)
- Testing
- Fosbretabulin, Carboplatin, Paclitaxel
- Where
- 15 sites in United States
- Volunteers
- 63 people
- Sponsor
- Mateon Therapeutics
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc